Yazar "Gokcan, Hale" seçeneğine göre listele

Listeleniyor 1 - 5 / 5
  • Küçük Resim Yok
    Öğe
    Identification of risk factors for alcohol relapse in liver transplant patients with alcohol-related liver disease
    (Elsevier, 2023) Turan, Dilara; Gunsar, Fulya; Harputluoglu, Murat; Kabacam, Gokhan; Gokcan, Hale; Akyildiz, Murat; Akarsu, Mesut
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Mushroom Intoxication in Türkiye: A Nationwide Cohort Study Based on Demographic Trends, Seasonal Variations, and the Impact of Climate Change on Incidence
    (Aves, 2025) Gokce, Dilara Turan; Ari, Derya; Ata, Naim; Gokcan, Hale; Idilman, Ramazan; Ulgu, Mustafa Mahir; Harputluoglu, Murat
    Background/Aims: Mushroom intoxication poses a considerable public health risk due to its potential for severe toxicity and fatality. This study aims to investigate demographic trends, diagnostic locations, and mortality rates of patients with mushroom intoxication. Materials and Methods: This retrospective cohort study utilized data from the National Electronic Database of the Turkish Ministry of Health. The study focused on patients without chronic liver disease or prior liver transplantation presenting with mushroom intoxication between 2018 and 2023. Demographic information, diagnostic locations, and mortality rates were analyzed, considering a six-year period to ensure even seasonal distribution. Results: Among 30 459 individuals admitted with mushroom intoxication, 44.75% were male, with a mean age of 45.84 years. The Black Sea, Marmara, and Central Anatolia regions had the highest number of cases, with specific cities like Tokat, Bolu, Yozgat, and Kastamonu having the highest rates per 100,000 population in 2022. Mushroom intoxication predominantly occurred in May, June, October, and November. Hospitalization occurred in 8.9% of cases, with a 6.6% mortality rate within 90 days and 1.3% progressing to liver transplantation. Notably, mushroom intoxication cases increased by 130% in the first half of 2023, particularly in May and June, correlating with increased rainfall. Conclusion: Mushroom intoxication is a serious public health issue, with morbidity and mortality influenced by climate factors. The study highlights a significant increase in cases in the first half of 2023, potentially linked to heightened rainfall and climate change.
  • Küçük Resim Yok
    Öğe
    Real life efficacy and tolerability of Tenofovir alafenamde fumarate in liver transplant recipients: a multicenter study
    (Elsevier, 2022) Gokcan, Hale; Yapali, Suna; Harputluoglu, Murat; Ellik, Zeynep Melekog. Lu; Gokcen, Pinar; Adanir, Haydar; Cosar, Arif Mansur
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    REAL LIFE EFFICACY AND TOLERABILITY OF TENOFOVIR ALAFENAMIDE FUMARATE IN PATIENTS WITH HEPATITIS B VIRUS-RELATED CIRRHOSIS AND LIVER TRANSPLANT RECIPIENTS. A-PRELIMINARY RESULT
    (Wiley, 2021) Yapali, Suna; Gokcan, Hale; Harputluoglu, Murat; Ellik, Zeynep Melekoglu; Akarsu, Mesut; Durak, Serdar; Gokcen, Pinar
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease
    (Kare Publ, 2023) Yilmaz, Yusuf; Zeybel, Mujdat; Adali, Gupse; Cosar, Arif Mansur; Sertesen, Elif; Gokcan, Hale; Bahcecioglu, Halil Ibrahim
    Nonalcoholic fatty liver disease (NAFLD) is a multisystem disease and is significantly associated with obesity, insulin resistance, type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease. NAFLD has become the most prevalent chronic liver disease in Western countries, and the proportion of NAFLD-related cirrhosis among patients on liver transplantation waiting lists has increased. In light of the accumulated data about NAFLD, and to provide a common approach with multi-disciplines dealing with the subject, it has become necessary to create new guidance for diagnosing and treating NAFLD. This guidance was prepared following an interdisciplinary study under the leadership of the Turkish Association for the Study of the Liver (TASL), Fatty Liver Special Interest Group. This new TASL Guidance is a practical application guide on NAFLD and was prepared to standardize the clinical approach to diagnosing and treating NAFLD patients. This guidance reflects many advances in the field of NAFLD. The proposals in this guidance are meant to aid decision-making in clinical practice. The guidance is primarily intended for gastroenterology, endocrinology, metabolism diseases, cardiology, internal medicine, pediatric specialists, and family medicine specialists.